Full Press Release Details
Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Application Submitted for the Treatment of Partial-Onset Seizures and Migraine
Eton's Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Topiramate
Topiramate Oral Solution is Eton's Third Neurology Product Candidate Submitted to the FDA
PARK, Ill., October 6, 2020 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company
focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that in tandem with
its development and manufacturing partner Tulex Pharmaceuticals, it has submitted a new drug application (NDA) for topiramate
oral solution to the U.S. Food & Drug Administration (FDA). The product candidate, formerly known as ET-101, was submitted
for three indications, including: monotherapy for treatment of partial-onset or primary general tonic-clonic seizures in patients
two years age and older; adjunctive therapy for treatment of partial-onset seizures, including seizures associated with Lennox-Gastaut
syndrome in patients two years of age and older; and as preventative treatment of migraine in patients 12 years of age and older.
is one of the most widely compounded oral liquids, and our product addresses the unmet need for pediatric-friendly formulations
of the molecule. We look forward to working with the FDA to bring a safe, effective, FDA-approved product to patients and caregivers
as quickly as possible," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
product is expected to be the first and only FDA-approved liquid formulation of topiramate. The company's patent-pending
liquid formulation addresses the significant unmet need for patients with dysphagia and patients that require the precision dosing
that a liquid can offer. Topiramate is currently FDA-approved only in tablet and capsule form. Based on IQVIA data, the market
for oral topiramate is more than $800 million annually.
is Eton's third neurology-focused liquid product candidates to be submitted to the FDA. Eton expects all three of the neurology
product candidates to be approved and launched in 2021.
Eton Pharmaceuticals
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for
rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved approved products, including
ALKINDI SPRINKLE, Biorphen , and Alaway Preservative Free, and has six additional products in its late-stage pipeline,
including five that have been submitted to the FDA.
contained in this press release regarding matters that are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability
of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited
to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates,
the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory
filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements
are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs
and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission.
All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes
no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they